These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32037141)

  • 1. Re: Aurélie De Bruycker, Elise De Bleser, Karel Decaestecker, et al. Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates. Eur Urol 2019;75:826-33: Nodal Recurrence of Prostate Cancer in Patients Treated with Radical Intent: Tailoring the Best Salvage Treatment.
    Montorsi F; Fossati N; Gandaglia G; Briganti A
    Eur Urol; 2020 May; 77(5):e137. PubMed ID: 32037141
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. Eur Urol 2019;76:732-9.
    Ghadjar P; Wiegel T
    Eur Urol; 2020 Mar; 77(3):e60-e61. PubMed ID: 31744642
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Pirus Ghadjar, Thomas Wiegel's Letter to the Editor re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome, Toxicity of Stereotactic Body Radiotherapy, Elective Nodal Radiotherapy. Eur Urol 2019;76:732-9.
    De Bleser E; Ost P
    Eur Urol; 2020 Mar; 77(3):e62-e63. PubMed ID: 31744645
    [No Abstract]   [Full Text] [Related]  

  • 4. Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates.
    De Bruycker A; De Bleser E; Decaestecker K; Fonteyne V; Lumen N; De Visschere P; De Man K; Delrue L; Lambert B; Ost P
    Eur Urol; 2019 May; 75(5):826-833. PubMed ID: 30503072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
    Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
    Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: Ost P, Siva S, Brabrand S, et al. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.007.
    Montorsi F; Gandaglia G; Barletta F; Briganti A
    Eur Urol Oncol; 2024 Oct; 7(5):1154. PubMed ID: 38418265
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Sophie Knipper, Mehrdad Mehdi Irai, Ricarda Simon, et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery. Eur Urol 2022;83:62-9.
    Pontes-Silva A
    Eur Urol; 2023 May; 83(5):e139. PubMed ID: 36797142
    [No Abstract]   [Full Text] [Related]  

  • 8. Salvage extended field or involved field nodal irradiation in
    Lépinoy A; Silva YE; Martin E; Bertaut A; Quivrin M; Aubignac L; Cochet A; Créhange G
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):40-48. PubMed ID: 30267117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reply from authors re: Guillaume Ploussard, James W. Catto. The quest for an optimal definition of prostate-specific antigen failure following radical prostatectomy: the risk of not seeing the forest for the trees. Eur Urol 2014;66:211-13: Identifying the candidates for early salvage therapy after radical prostatectomy.
    Mir MC; Stephenson AJ
    Eur Urol; 2014 Aug; 66(2):213. PubMed ID: 24176596
    [No Abstract]   [Full Text] [Related]  

  • 10. Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.
    Sharma V; Nehra A; Colicchia M; Westerman ME; Kawashima A; Froemming AT; Kwon ED; Mynderse LA; Karnes RJ
    Eur Urol; 2018 Jun; 73(6):879-887. PubMed ID: 29195777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Salvage brachytherapy for prostate cancer biochemical recurrence after radiotherapy].
    Rubio AP; López IJ
    Arch Esp Urol; 2012; 65(1):145-57. PubMed ID: 22318185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage radical prostatectomy for recurrent prostate cancer after radiation therapy.
    Leonardo C; Simone G; Papalia R; Franco G; Guaglianone S; Gallucci M
    Int J Urol; 2009 Jun; 16(6):584-6. PubMed ID: 19453762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET/CT and MRI directed extended salvage radiotherapy in recurrent prostate cancer with lymph node metastases.
    Rischke HC; Eiberger AK; Volegova-Neher N; Henne K; Krauss T; Grosu AL; Jilg CA
    Adv Med Sci; 2016 Sep; 61(2):212-218. PubMed ID: 26895459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of early prostate-specific antigen values after salvage radiotherapy in recurrent prostate cancer patients treated with surgery.
    Chang JH; Park W; Park JS; Pyo H; Huh SJ; Choi HY; Lee HM; Jeon SS; Seo SI
    Int J Urol; 2015 Jan; 22(1):82-7. PubMed ID: 25208624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
    Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
    Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of Recurrence After Salvage Radiotherapy Encompassing Pelvic Lymphatics in Men with High-risk Prostate Cancer.
    Koh M; Kim YS; Ahn H; Kim CS
    Anticancer Res; 2018 Nov; 38(11):6579-6584. PubMed ID: 30396989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligorecurrent Nodal Prostate Cancer: Long-term Results of an Elective Nodal Irradiation Approach.
    Tran S; Jorcano S; Falco T; Lamanna G; Miralbell R; Zilli T
    Am J Clin Oncol; 2018 Oct; 41(10):960-962. PubMed ID: 29315174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol 2019;76:27-30: Salvage Robotic Radical Prostatectomy for Recurrent Prostate Cancer After Focal Therapy.
    Marra G; Van Velthoven R; Valerio M
    Eur Urol; 2020 Apr; 77(4):e103-e104. PubMed ID: 31607392
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy.
    Song W; Jeon HG; Sung HH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
    Int J Urol; 2016 Jan; 23(1):56-61. PubMed ID: 26502086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage radiotherapy for prostate-specific antigen relapse after radical prostatectomy for prostate cancer: a single-center experience.
    Yoshida T; Nakayama M; Suzuki O; Matsuzaki K; Kobayashi Y; Takeda K; Arai Y; Kakimoto K; Nishiyama K; Nishimura K
    Jpn J Clin Oncol; 2011 Aug; 41(8):1031-6. PubMed ID: 21693484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.